Menten AI designs peptide and protein therapeutics using quantum…
Company research
Public company, workplace, funding, and market signals
Overview
Menten AI is a San Francisco-based, remote-first biotechnology company that builds MAUD 1.0, a generative-AI platform for de novo design of cyclic peptide macrocycles and other peptide therapeutics, with an emphasis on hard-to-drug targets such as protein-protein interfaces.
Primary product
MAUD 1.0 generative AI platform for de novo cyclic peptide / macrocycle drug design
Founded
2020
Headquarters
San Francisco, California, United States
Team size
10-20
Work style
Remote
Industry
Biotechnology Research
Sub-industry
AI drug discovery / peptide therapeutics
Offices
Open Positions
0 jobs at Menten AI
No open positions
Check back later for new openings